Zomedica Corp. 8-K

What Happened

• Zomedica Corp. (ZOMDF) filed an 8-K (June 11, 2026) reporting the results of its annual meeting held June 10, 2026. Shareholders elected all eight director nominees to one-year terms (through the 2027 annual meeting), ratified the appointment of Grant Thornton LLP as auditor for fiscal 2026, rejected the non-binding advisory vote on executive compensation, and approved a by‑law amendment regarding quorum for adjourned shareholder meetings.

Key Details

• Meeting date: June 10, 2026; Form 8-K filed June 11, 2026 (Item 5.07).
• Proposal 1 — Election of eight directors (For / Withheld / Broker Non-Vote):
  • Jeffrey Rowe: 148,970,700 / 80,211,388 / 200,401,611
  • Robert Cohen: 141,153,095 / 88,028,993 / 200,401,611
  • Chris Macleod: 141,041,101 / 88,140,987 / 200,401,611
  • Pam Nichols: 146,791,443 / 82,390,645 / 200,401,611
  • Johnny D. Powers: 151,457,102 / 77,724,986 / 200,401,611
  • Sean Whelan: 141,437,085 / 87,745,003 / 200,401,611
  • Rodney Williams: 141,615,934 / 87,566,154 / 200,401,611
  • Larry Heaton: 148,997,578 / 80,184,510 / 200,401,611
• Proposal 2 — Ratification of independent auditor: For 403,285,558; Withheld 26,298,141. Grant Thornton LLP ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Proposal 3 — Advisory vote on executive compensation (non-binding): For 99,891,977; Against 129,290,109; Broker Non-Vote 200,401,613. The compensation proposal did not pass.
• Proposal 4 — Amendment to By-Laws (quorum for adjourned meetings): For 123,410,315; Against 105,771,772; Broker Non-Vote 200,401,613. The amendment was approved.

Why It Matters

• Board composition and auditor ratification were confirmed, which reduces near-term governance uncertainty. The failed advisory vote on executive compensation is non-binding, but it signals significant shareholder dissatisfaction with pay practices; the board may respond with disclosure changes or compensation adjustments in future proxy materials. The by‑law amendment changes internal meeting procedures (quorum at adjourned meetings), affecting how future shareholder votes may be conducted.